Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | MMP9 | P14780 | 4/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.60 |
| ▸ | BACE1 | P56817 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.60 |
| ▸ | STAT3 | P40763 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805181 | 0.95 | APP (0.69) | APPMAPTMMP9NFKB1BACE1 | |
| SCHEMBL3220601 | 0.88 | MAPT (1.00) | APPMAPTMMP9NFKB1BACE1 | |
| SCHEMBL3220571 | 0.88 | MAPT (1.00) | APPMAPTMMP9NFKB1BACE1 | |
| SCHEMBL3223017 | 0.81 | MAPT (0.87) | APPMAPTMMP9NFKB1BACE1 | |
| SCHEMBL3222988 | 0.81 | MAPT (0.87) | APPMAPTMMP9NFKB1BACE1 | |
| SCHEMBL30663618 | 0.81 | APP (0.86) | APPMAPTMMP9NFKB1BACE1 | |
| SCHEMBL1378809 | 0.78 | APP (0.80) | APPMAPTMMP9NFKB1BACE1 | |
| Curcumin SCHEMBL17629819 | 0.77 | APP (1.00) | APPMAPTMMP9NFKB1BACE1 | |
| Curcumin SCHEMBL8336603 | 0.77 | APP (1.00) | APPMAPTMMP9NFKB1BACE1 | |
| Curcumin SCHEMBL250984 | 0.77 | APP (1.00) | APPMAPTMMP9NFKB1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC. | 2024-06-06 | — | — | US | claimed |
| EP-4301469-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | Signpath Pharma, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| CN-116963724-A | Treatment for human malignant pleural effusion | 萨恩帕斯药物有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116710123-A | Cytokine release and inhibition of cytokine storm | 萨恩帕斯药物有限公司 | 2023-09-05 | — | — | CN | claimed |
| EP-4188398-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | Signpath Pharma, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022187351-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022026170-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | SIGNPATH PHARMA, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| WO-2004080396-A2 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (US) | 2004-09-23 | — | — | WO | claimed |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | disclosed |
| US-12551436-B2 | Dosing regimens for treatment of proliferative disorders | SIGNPATH PHARMA INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3773529-B1 | DOSING REGIMENS FOR TREATMENT OF PROLIFERATIVE DISORDERS | SIGNPATH PHARMA INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12478576-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4591711-A1 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | Albert Einstein College of Medicine (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2022026170-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | SIGNPATH PHARMA, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-112272555-A | Dosing regimens for treating proliferative disorders | 萨恩帕斯药物有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. | 2018-11-08 | — | — | US | disclosed |
| CN-105294756-B | Amido phosphate bis-curcumin ester compound, preparation method and application | 北京理工大学 | 2017-05-10 | — | — | CN | disclosed |
| EP-3057578-A1 | COMPOSITION FOR THE ORAL ADMINISTRATION OF CURCUMIN | BRIU GmbH (DE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015055193-A1 | COMPOSITION FOR THE ORAL ADMINISTRATION OF CURCUMIN | BRIU GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | APP 1031/4885MAPT 1646/4885MMP9 1825/4885 |
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | MTDH, PLEC, LPCAT3 | APP 3737/4885MAPT 3156/4885MMP9 1592/4885 |
| US-12551436-B2 | Dosing regimens for treatment of proliferative disorders | CCND2, CCND1, CCNE2 | APP 2297/4885MAPT 1296/4885MMP9 2044/4885 |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | CCND1, CCND2, CCNE2 | APP 581/4885MAPT 503/4885MMP9 1264/4885 |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | LIPA, LPCAT3, LCLAT1 | APP 1019/4885MAPT 1067/4885MMP9 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.